The new study, spearheaded by experts at UCL and the universities of Cambridge and Edinburgh, with support from the BHF Data Science Centre at Health Data Research UK, analyzed health records from 13.9 million children under the age of 18 from January 1, 2020, to December 31, 2022, reports the Express.

The Pfizer Covid vaccine increased the risk of heart problems for children sixfold in the first week of having the jab but led to fewer cases in the long term, research suggests.

The new Moderna COVID vaccine, mNexspike, is approved for adults 65 and older and people 12 to 64 with an underlying medical condition that puts them at higher risk for severe COVID.

Taking a closer look at the numbers, Comirnaty sales slipped 19% globally to $1.15 billion, the Prevnar franchise experienced a 3% global sales decline to $1.7 billion, and Abrysvo’s performance decreased 22% to sales of $279 million in Q3.

Pfizer said today its COVID-19 vaccine has saved more than 14 million lives worldwide, after President Donald Trump urged pharmaceutical companies to justify the success of their pandemic drugs. In a post on Truth Social, Trump asserted that he has seen ...

Children, young people were more likely to experience heart, vascular or inflammatory problems after a COVID-19 infection than after having vaccine,' say scientists - Anadolu Ajansı

Pfizer also has set its sights on becoming a giant in oncology, and to support this, completed the acquisition of Seagen in 2023. Two of Seagen's products in the most recent quarter delivered double-digit growth, and Seagen's technology and pipeline offer Pfizer the opportunity to further expand its oncology portfolio.

Sept 15 (Reuters) - Pfizer Inc (PFE.N), opens new tab said on Tuesday participants were showing mostly mild-to-moderate side effects when given either the company's experimental coronavirus vaccine or a placebo in an ongoing late-stage study. The company ...

Pfizer has axed 11 programs, including two pipeline assets from its $43 billion Seagen acquisition, work on a BioNTech-partnered mRNA vaccine and a midstage MASH combo.